Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Siscard

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 197Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aisa Pharma Reports Positive Phase 2 Trial Of AISA-021
    Aisa Pharma Reports Positive Phase 2 Trial Of AISA-021

    06 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aisa-pharma-announces-encouraging-results-from-phase-2-reconnoiter-trial-of-aisa-021-cilnidipine-in-patients-with-systemic-sclerosisassociated-raynauds-phenomenon-302705901.html

    PR NEWSWIRE
    06 Mar 2026
    Share Share
    NPPA fixes retail price of 20 new drugs
    NPPA fixes retail price of 20 new drugs

    04 Mar 2026

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=184549&sid=1

    PHARMABIZ
    04 Mar 2026
    Share Share
    AISA Pharma Announces Start of Ph2b Profervia® Study for Raynaud's Phenomenon
    AISA Pharma Announces Start of Ph2b Profervia® Study for Raynaud's Phenomenon

    21 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aisa-pharma-announces-start-of-phase-2b-profervia-study-for-raynauds-phenomenon-in-systemic-sclerosis-ssc-301856151.html

    PR NEWSWIRE
    21 Jun 2023
    Share Share
    NPPA fixes retail prices of 22 formulations under DPCO, 2013
    NPPA fixes retail prices of 22 formulations under DPCO, 2013

    06 May 2019

    // PHARMABIZ

    http://pharmabiz.com/ArticleDetails.aspx?aid=115527&sid=1

    PHARMABIZ
    06 May 2019
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.